Trial Profile
Randomized control trial of Abiraterone and Enzalutamide for castration resistant prostate cancer patients.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 May 2020
Price :
$35
*
At a glance
- Drugs Abiraterone (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms Abenza
- 16 May 2016 New trial record